Morning Market Gainers

shares surged 30.27 percent to $8.78 following announcement of results of ARC-520 Hep B study.

shares gained 28.16 percent to $3.55 after the company reported extension of private debt exchange offers and support agreement.

shares jumped 16.90 percent to $6.71 after the company reported top-line results from Multicenter Phase 2 Portal Hypertension clinical trial in patients with liver cirrhosis.

shares gained 14.58 percent to $2.75 after the company reported the publication of CoSense clinical data in the journal Neonatology.

shares rose 13.64 percent to $1.75. Dataram reported that it has regained compliance with NASDAQ listing requirements.

shares gained 7.65 percent to $4.22 following announcement of the EU approval for Fexericx for the treatment of hyperphosphatemia in adults with chronic kidney disease.